Here's the Colombian study conclusions, taken directly from
https://rebelem.com/covid-19-update-ivermectin/
"
Author Conclusion: “Among adults with mild COVID-19, a 5-day course of ivermectin, compared with placebo, did not significantly improve the time to resolution of symptoms. The findings do not support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.”"
So in this particular study, no benefit was observed. From the author of the site:
"
Bottom Line: This randomized, double-blinded, placebo-controlled trial showed no benefit to the use of ivermectin compared to placebo in resolution of symptoms by 21 days. The methodology of this trial is certainly of better quality than previous trials, however there are some clear short comings with errors and potential for unblinding. Also, the relatively young and healthy study population included in this trial makes it difficult to extrapolate conclusions to older patient populations and/or patients with comorbid disease. We will just have to wait and see what future trials in different patient populations show."
Clinical Question: Does Ivermectin demonstrate efficacy in prophylaxis and treatment of COVID-19?
rebelem.com
So the study in essence was mostly methodologically sound but still with some short-comings. It found no observable benefit using ivermectin. However, the focus on young people means we can't extrapolate this to other older patients who might have covid and are treated with ivermectin.
In other words, a study that is interesting but inconclusive. I like this site as it looks at each study, makes an assessment of the methodology, and seems to make fair conclusions.